Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters

Viruses

Volumn 7, Issue 3, 2015, Pages 1409-1428

  Toth, Karoly ^a   Ying, Baoling ^a   Tollefson, Ann E ^a   Spencer, Jacqueline F ^a   Balakrishnan, Lata ^b   Sagartz, John E ^a   Buller, Robert Mark L ^a   Wold, William S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Adenovirus; Antiviral; Hamster; Valganciclovir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BRINCIDOFOVIR; CIDOFOVIR; DNA BINDING PROTEIN; DNA POLYMERASE; GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DISEASE SEVERITY; DNA REPLICATION; DRUG EFFICACY; EC50; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN ADENOVIRUS 5; HUMAN ADENOVIRUS INFECTION; IC50; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE TEST; INFECTION PREVENTION; LIVER INJURY; MALE; NONHUMAN; PLAQUE ASSAY; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SURVIVAL; SYRIAN HAMSTER; VIRUS GENE; VIRUS REPLICATION; WESTERN BLOTTING; ADENOVIRUS INFECTIONS, HUMAN; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; HUMAN; HUMAN ADENOVIRUS C; IMMUNOCOMPROMISED PATIENT; LIVER; MESOCRICETUS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADENOVIRIDAE; CRICETINAE; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; MESOCRICETUS AURATUS;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; DNA-DIRECTED DNA POLYMERASE; EPITHELIAL CELLS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; LIVER; MALE; MESOCRICETUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84925845408     PISSN: 19994915     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7031409     Document Type: Article

References (38)

1. Wold, W.S.M.; Ison, M.G. Adenoviruses. In Fields Virology, Knipe, D.M.; Howley, P.M., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2013; p. 1732.
2. Lion, T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin. Microbiol. Rev. 2014, 27, 441–62.
3. Matthes-Martin, S.; Boztug, H.; Lion, T. Diagnosis and treatment of adenovirus infection in immunocompromised patients. Expert review of anti-infective therapy 2013, 11, 1017–28.
4. Matthes-Martin, S.; Feuchtinger, T.; Shaw, P.J.; Engelhard, D.; Hirsch, H.H.; Cordonnier, C.; Ljungman, P.; Fourth European Conference on Infections in Leukemia. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: Summary of ECIL-4 (2011). Transplant infectious disease: An official journal of the Transplantation Society 2012, 14, 555–63.
5. Sandkovsky, U.; Vargas, L.; Florescu, D.F. Adenovirus: Current epidemiology and emerging approaches to prevention and treatment. Current infectious disease reports 2014, 16, 416.
6. Coen, D.M.; Richman, D.D. Antiviral Agents. In Fields Virology, 6th ed.; Knipe, D.M.; Howley, P.M., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2013; Vol. 1, pp 338–373.
7. Florescu, D.F.; Pergam, S.A.; Neely, M.N.; Qiu, F.; Johnston, C.; Way, S.; Sande, J.; Lewinsohn, D.A.; Guzman-Cottrill, J.A.; Graham, M.L.; Papanicolaou, G.; Kurtzberg, J.; Rigdon, J.; Painter, W.; Mommeja-Marin, H.; Lanier, R.; Anderson, M.; van der Horst, C. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol. Blood Marrow Transplant. 2012, 18, 731–8.
8. Paolino, K.; Sande, J.; Perez, E.; Loechelt, B.; Jantausch, B.; Painter, W.; Anderson, M.; Tippin, T.; Lanier, E.R.; Fry, T.; DeBiasi, R.L. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. J. Clin. Virol. 2011, 50, 167–70.
9. Tollefson, A.E.; Spencer, J.F.; Ying, B.; Buller, R.M.; Wold, W.S.; Toth, K. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Res. 2014, 112, 38–46.
10. Toth, K.; Spencer, J.F.; Dhar, D.; Sagartz, J.E.; Buller, R.M.; Painter, G.R.; Wold, W.S. M. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 7293–7297.
11. Wold, W.S.; Toth, K. Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv. Cancer Res. 2012, 115, 69–92.
12. Dhar, D.; Spencer, J.F.; Toth, K.; Wold, W.S.M. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J. Virol. 2009, 83, 2130–2139.
13. Dhar, D.; Toth, K.; Wold, W.S. M. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Ther. 2014.
14. Thomas, M.A.; Spencer, J.F.; Toth, K.; Sagartz, J.E.; Phillips, N.; Wold, W.S.M. Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol. Ther. 2008, 16, 1665–1673.
15. Lichtenstein, D.L.; Spencer, J.F.; Doronin, K.; Patra, D.; Meyer, J.M.; Shashkova, E.V.; Kuppuswamy, M.; Dhar, D.; Thomas, M.A.; Tollefson, A.E.; Zumstein, L.A.; Wold, W.S.; Toth, K. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther. 2009, 16, 644–54.
16. Ying, B.; Toth, K.; Spencer, J.F.; Meyer, J.; Tollefson, A.E.; Patra, D.; Dhar, D.; Shashkova, E.V.; Kuppuswamy, M.; Doronin, K.; Thomas, M.A.; Zumstein, L.A.; Wold, W.S.; Lichtenstein, D.L. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: Comparison of biodistribution studies. Cancer Gene Ther. 2009, 16, 625–37.
17. Echavarria, M. Adenoviruses in immunocompromised hosts. Clin. Microbiol. Rev. 2008, 21, 704–715.
18. Ison, M.G. Adenovirus infections in transplant recipients. Clin. Infect. Dis. 2006, 43, 331–9.
19. Lenaerts, L.; Kelchtermans, H.; Geboes, L.; Matthys, P.; Verbeken, E.; De Clercq, E.; Naesens, L. Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection. Antimicrob. Agents Chemother. 2008, 52, 1462–1471.
20. Lindemans, C.A.; Leen, A.M.; Boelens, J.J. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010, 116, 5476–5485.
21. Ying, B.; Tollefson, A.E.; Spencer, J.F.; Balakrishnan, L.; Dewhurst, S.; Capella, C.; Buller, R.M.; Toth, K.; Wold, W.S. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. Antimicrob. Agents Chemother. 2014, 58, 7171–81.
22. Levitsky, J.; Singh, N.; Wagener, M.M.; Stosor, V.; Abecassis, M.; Ison, M.G. A survey of CMV prevention strategies after liver transplantation. American journal of transplantation: Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008, 8, 158–61.
23. Sugawara, M.; Huang, W.; Fei, Y.J.; Leibach, F.H.; Ganapathy, V.; Ganapathy, M.E. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT 2. J. Pharm. Sci. 2000, 89, 781–9.
24. Lillie, J.W.; Loewenstein, P.M.; Green, M.R.; Green, M. Functional domains of adenovirus type 5 E1a proteins. Cell 1987, 50, 1091–1100.
25. Cepko, C.L.; Whetstone, C.A.; Sharp, P.A. Adenovirus hexon monoclonal antibody that is group specific and potentially useful as a diagnostic reagent. J. Clin. Microbiol. 1983, 17, 360–4.
26. Thomas, G.P.; Mathews, M.B. DNA replication and the early to late transition in adenovirus infection. Cell 1980, 22, 523–533.
27. Sugawara, K.; Gilead, Z.; Wold, W.S.M.; Green, M. Immunofluorescence study of the adenovirus type 2 single- stranded DNA binding protein in infected and transformed cells. J. Virol. 1977, 22, 527–539.
28. Voelkerding, K.; Klessig, D.F. Identification of two nuclear subclasses of the adenovirus type 5-encoded DNA-binding protein. J. Virol. 1986, 60, 353–362.
29. Dhar, D.; Spencer, J.F.; Toth, K.; Wold, W.S.M. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol. Ther 2009, 17, 1724–1732.
30. Avivi, I.; Chakrabarti, S.; Milligan, D.W.; Waldmann, H.; Hale, G.; Osman, H.; Ward, K.N.; Fegan, C.D.; Yong, K.; Goldstone, A.H.; Linch, D.C.; Mackinnon, S. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol. Blood Marrow Transplant. 2004, 10, 186–194.
31. Blohme, I.; Nyberg, G.; Jeansson, S.; Svalander, C. Adenovirus infection in a renal transplant patient. Transplant. Proc. 1992, 24, 295.
32. Bruno, B.; Gooley, T.; Hackman, R.C.; Davis, C.; Corey, L.; Boeckh, M. Adenovirus infection in hematopoietic stem cell transplantation: Effect of ganciclovir and impact on survival. Biol. Blood Marrow Transplant. 2003, 9, 341–352.
33. Chen, F.E.; Liang, R.H.; Lo, J.Y.; Yuen, K.Y.; Chan, T.K.; Peiris, M. Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant. 1997, 20, 997–9.
34. Duggan, J.M.; Farrehi, J.; Duderstadt, S.; Turner, N.J.; Fekety, R. Treatment with ganciclovir of adenovirus pneumonia in a cardiac transplant patient. Am. J. Med. 1997, 103, 439–40.
35. Lenaerts, L.; De Clercq, E.; Naesens, L. Clinical features and treatment of adenovirus infections. Rev.Med.Virol. 2008, 18, 357–374.
36. Yabiku, S.T.; Yabiku, M.M.; Bottos, K.M.; Araujo, A.L.; Freitas, D.; Belfort Jr, R. [Ganciclovir 0.15% ophthalmic gel in the treatment of adenovirus keratoconjunctivitis]. Arq. Bras. Oftalmol. 2011, 74, 417–21.
37. Asberg, A.; Humar, A.; Rollag, H.; Jardine, A.G.; Mouas, H.; Pescovitz, M.D.; Sgarabotto, D.; Tuncer, M.; Noronha, I.L.; Hartmann, A.; Group, V.S. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. American journal of transplantation: Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2007, 7, 2106–13.
38. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Available online: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078932.pdf (accessed on 19 March 2015).